In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topica Pharmaceuticals Inc.

Latest From Topica Pharmaceuticals Inc.

Deals Shaping the Medical Industry (03/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.

Medical Dermatology Gets Under VCs' Skin

In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.


Topica Pharmaceuticals

Topica began its life with a promising novel anti-fungal called luliconazole (Lulicon) in hand. The compound was developed by Nihon Nohyaku and is already approved in Japan for tinea infections. Topica's initial focus will be on advancing ongoing clinical trials of the drug in athlete's foot, but even as it begins studies in athlete's foot, a market IMS estimates to be approximately $400 million in the US alone, the end goal is a topical treatment for onychomycosis.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Janus Pharmaceuticals
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Topica Pharmaceuticals Inc.
  • Senior Management
  • Joseph Golemme, CFO
    Norifumi Nakamura, PhD, SVP, Research & Corp. Dev.
  • Contact Info
  • Topica Pharmaceuticals Inc.
    Phone: (650) 473-3800
    435 Tasso St.
    Ste. 325
    Palo Alto, CA 94301